Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study

Lancet

Volumn 356, Issue 9245, 2000, Pages 1876-1881

  Narod, Steven A ^a,l   Brunet, Jean Sébastien ^b   Ghadirian, Parviz ^c   Robson, Mark ^d   Heimdal, Ketil ^e   Neuhausen, Susan L ^f   Stoppa Lyonnet, Dominique ^g   Lerman, Caryn ^h   Pasini, Barbara ⁱ   De Los Rios, Patricia ^a   Weber, Barbara ^j   Lynch, Henry ^k  

^a UNIVERSITY OF TORONTO   (Canada)

^b Senneville   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g INSTITUT CURIE   (France)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l WOMEN S COLLEGE HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OVARIECTOMY; PRIORITY JOURNAL;

EID: 0034597916     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03258-X     Document Type: Article

References (34)

1. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families
2. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
3. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
4. Population-based study of risk of breast cancer in carriers of BRCA2 mutation
5. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
6. BRCA-associated breast cancer in young women
7. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
8. Recommendations for follow-up care of individuals with an inherited predisposition to cancer BRCA1 and BRCA2
9. Tamoxifen for prevention of breast cancer, report of the National Surgical Adjuvant Breast and Bowel Project PI study
10. Tamoxifen for early breast cancer an overview of the randomised trial
11. Rapid detection of BRCA1 mutations by the protein truncation test
12. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families
13. Founder BRCA1 and BRCA2 mutations in French-Canadian breast and ovarian cancer families
14. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status in breast cancers in Ashkenazi Jewish women
15. Tumour biological features of BRCA1-induced breast and ovarian cancer
16. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes
17. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes
18. Risk modifiers in carriers of BRCA1 mutations
19. Breast and ovarian cancer incidence in BRCA1 mutation carriers
20. Reduction in breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
21. Pregnancy and risk of early onset breast cancer in carriers of BRCA1 and BRCA2
22. The effect of smoking on breast cancer incidence in BRCA1 and BRCA2 carriers
23. BRCA1 inhibition of estrogen receptor signalling in transfected cells
24. Prevention of breast cancer with tamoxifen preliminary findings from the Italian randomized trial among hysterectomised women
25. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
26. Risks of cancer in BRCA1-mutation carriers
27. Cancer risks in BRCA2 carriers
28. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer
29. The effect of raloxifene on risk of breast cancer in postmenopausal women results from the MORE randomized trial
30. Epidemiology of contralateral breast cancer
31. Pathology of familial breast cancer differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
32. p55 Mutations in BRCA1-associated familial breast cancer
33. Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast
34. Tamoxifen and contralateral breast cancer